Sat.Nov 16, 2024 - Fri.Nov 22, 2024

article thumbnail

Providers, payers focused on initial 'quick wins' for AI with plans to grow investment: survey

Fierce Healthcare

More than half of health system and health plan executives say AI is an immediate priority, and 73% are increasing their investments in the technology, a new C-suite survey finds. | More than half of health system and health plan executives say AI is an immediate priority, and 73% are increasing their investments in the technology, a new C-suite survey finds.

139
139
article thumbnail

H5N1 Bird Flu: A Slowly Looming Public Health Threat

Drug Topics

Public health and infectious disease experts offered their perspectives on the 2024 US bird flu outbreak and its potential of becoming a greater public health crisis.

220
220
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: AI in drug discovery is ‘nonsense,’ but call Schrödinger ‘AI’ if you want, says CEO

STAT

Schrödinger CEO Ramy Farid wants you to know that his company isn’t an AI company…but he’ll call it that if you want to. The company, founded in 1990, started out by making software that used the basic laws of physics to laboriously and exactly predict how molecules will interact with each other in space. Those calculations, rooted in the field of computational physics, needed lots of expensive and time-consuming computing power to run, and many people abandoned those t

139
139
article thumbnail

Clinical Safety Data Show Switching Between Rituximab Biosimilars Does Not Increase Adverse Events

Pharmacy Times

There were 2 main types of switches, including switching to rituximab subcutaneous and switching among different intravenous rituximab treatments.

156
156
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Smart ring maker Oura picks up $75M series D, inks strategic partnership with Dexcom

Fierce Healthcare

Oura is partnering with medical device maker Dexcom to integrate data from glucose biosensors with the Oura Ring, which tracks sleep, heart rate and activity. | Oura is partnering with medical device maker Dexcom to integrate data from glucose biosensors with the Oura Ring.

143
143
article thumbnail

Medication Optimization Needed for Patients with Long COVID

Drug Topics

Investigators said there is an imperative to optimize medication utilization and explore the consequences of medication burden on treatment outcomes in patients with long COVID.

218
218

More Trending

article thumbnail

FDA Grants Rare Pediatric Disease Designation for Treatment of Neonatal SP-B Deficiency

Pharmacy Times

The disorder presents as severe lung disease, with lung transplantation as the only current therapeutic option for long-term survival.

FDA 153
article thumbnail

FDA advisory committee to roll up sleeves on generative AI

Fierce Healthcare

The FDA will hold its first Digital Health Advisory Committee (DHAC) meeting to discuss how the agency should review medical devices that rely on generative AI, like chatbots. | The FDA seeks advice on regulatory challenges it has identified for generative AI used in medical devices, which include uncertainty about the foundation model, hallucinations and the ability to define intended use.

FDA 139
article thumbnail

Tai Chi Intervention, Liver Disease Prevalence for People with OA | ACR Convergence

Drug Topics

Researchers explored the benefits of tai chi and prevalence of liver disease in patients with osteoarthritis.

198
198
article thumbnail

STAT+: RFK Jr. is exploring a plan to upend Medicare’s physician payments system

STAT

WASHINGTON  — People close to Robert F. Kennedy Jr. are exploring a proposal that could upend how physician payment is determined in America, four sources familiar with the process told STAT.

145
145
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes

Pharmacy Times

In this episode of Public Health Matters, Christina Madison discusses pharmacist-physician collaborations with Amina Abubakar and Stephen Lewis.

144
144
article thumbnail

AstraZeneca to go on defense for Andexxa as FDA questions bleeding reversal agent's safety ahead of adcomm

Fierce Pharma

As a council of outside experts prepares to meet Thursday to discuss AstraZeneca’s Andexxa, the FDA has flagged “major safety findings” linked to the British drugmaker’s bleeding reversal agent.

FDA 131
article thumbnail

Despite Benefits, Mediterranean Diet Adherence in RA Remains Low | ACR Convergence

Drug Topics

The Mediterranean diet is largely considered one of the healthiest diets.

187
187
article thumbnail

Opinion: The FDA’s risky action on compounding weight loss drugs

STAT

When Makena, a drug designed to prevent preterm births, hit the market in 2011 at $1,500 per dose, it drew rife backlash. The drug was based on an active ingredient that had been available for many years at a much lower cost. Confronted with the public outcry, the FDA took an unusual step: It allowed pharmacies to continue making their own copies of the drug through the practice of pharmacy compounding, selling it at a fraction of Makena’s price.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Spread of Seasonal Flu Returns to Pre-Pandemic Levels After End of COVID-19 Global Emergency

Pharmacy Times

Increased global capacity for surveillance could help monitor seasonal influenza to reduce the risk of vaccine mismatch and inform effective interventions.

Vaccines 145
article thumbnail

Former Oak Street CEO Mike Pykosz leaves CVS

Fierce Healthcare

Mike Pykosz, the former CEO of Oak Street Health, will leave CVS Health as part of the company's latest leadership shake-up. | Mike Pykosz, the former CEO of Oak Street Health, will leave CVS Health as part of the company's latest leadership shake-up.

131
131
article thumbnail

Outcomes Vary When Cannabis Is Used for Pain Management in Rheumatic Disease | ACR Convergence

Drug Topics

Investigators evaluated the role that cannabis plays in pain management in different populations with rheumatic diseases.

187
187
article thumbnail

AI-guided decisions can devastate lower-income Americans. This group wants to change that

STAT

In 2016, the Arkansas Legal Aid Center was flooded with calls. People on a Medicaid program that provided in-home care assistance were having their caregiving hours cut. Reducing the hours for somebody with quadriplegia or cerebral palsy was devastating, said Kevin De Liban, an attorney with the organization at the time. “People are lying in their own waste, people are getting bed sores from not being turned.

137
137
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

CHMP Recommends Lazertinib With Amivantamab to Treat EGFR-Mutated Advanced NSCLC

Pharmacy Times

Lazertinib in combination with amivantamab displays positive outcomes for non–small cell lung cancer compared with standard first line treatment.

145
145
article thumbnail

Expiration of hospital-at-home, telehealth policies threatens nonprofit hospitals' recovery: Fitch

Fierce Healthcare

Not-for-profit hospital and health systems are slowly recovering from their worst year financially in 2022. | If federal lawmakers don't act to extend the Acute Hospital Care at Home program, which expires at the end of this year, it could dampen not-for-profit hospitals' nascent financial recovery, according to a new report from Fitch Ratings.

Hospitals 128
article thumbnail

PMDD More Prevalent in RA, Leading to Worsened Mental Health | ACR Convergence

Drug Topics

Premenstrual Dysphoric Disorder is considered a psychiatric disorder and is associated with moderate to severe physical, affective, and behavioral symptoms.

184
184
article thumbnail

STAT+: Kura licenses leukemia drug to Japanese drugmaker

STAT

Kura Oncology has signed a global partnership with the Japanese drugmaker Kyowa Kirin to develop and sell Kura’s experimental treatment for acute leukemia, the companies said Wednesday.  Kyowa is paying $320 million to Kura in exchange for global licensing rights to the drug, called ziftomenib, which is in a late-stage clinical trial for a genetically defined type of advanced leukemia.

130
130
article thumbnail

AHA 2024: Tirzepatide Lowers Risk of Worsening Heart Failure, CVD Death in Adults With Obesity

Pharmacy Times

This is the first trial that tested the effect of any medication on major heart failure outcomes in patients with HFpEF and obesity, according to investigators.

145
145
article thumbnail

Roche files patent suit to fend off potential Evrysdi generics from Zydus, Natco

Fierce Pharma

Roche's spinal muscular atrophy (SMA) medicine Evrysdi only gained its FDA approval in 2020, but generics companies are already eying the blockbuster as a potential target. | The spinal muscular atrophy drug is a growth driver for the Swiss pharma giant, prompting the company to prioritize its defense against potential generics.

FDA 128
article thumbnail

An emerging cyberthreat: vishing

Fierce Healthcare

Cyberattacks against healthcare organizations are becoming increasingly sophisticated, with new threats constantly emerging. | This week on "Podnosis," we explore the rise of voice phishing, or vishing, where cybercriminals use AI to mimic voices and breach sensitive healthcare data.

126
126
article thumbnail

STAT+: Pharma still ‘falling short’ in providing access to low- and middle-income countries, analysis finds

STAT

Although more pharmaceutical companies are tailoring their business models to focus on low-income countries, a new analysis finds that overall industry efforts remain limited and patient access continues to suffer as a result. Notably, momentum has stalled in reaching licensing deals that are designed to make lower-cost generic drugs available in parts of the world where brand-name medicines are unaffordable, and few companies have pursued technology transfer agreements.

article thumbnail

Antibody Drug Conjugate Targeting CLDN1 Receives FDA Fast Track Designation

Pharmacy Times

ALE.P02 could provide further treatment options for advanced or metastatic anti–claudin-1+ squamous cancers.

FDA 139
article thumbnail

Johnson & Johnson, Merck lay off workers in China as local headwinds take a toll

Fierce Pharma

Johnson & Johnson and Merck are laying off workers in Chi | Johnson & Johnson and Merck are laying off workers in China, according to a story from Bloomberg which cites reports from Chinese news outlets.

128
128
article thumbnail

Payer Roundup—CVS insider trading scandal; DOJ closely examining PBMs

Fierce Healthcare

Below is a roundup of payer-centric news headlines you may have missed during the month of November 2024. | In this month's payer roundup, a man was charged with insider trading for purchasing Oak Street Health stock before CVS made public the acquisition, the DOJ is honing in on pharmacy benefit managers and OIG found Medicare improperly paid acute-care hospitals by $190 million.

Hospitals 124
article thumbnail

STAT+: AHA 2024: First, a call for prevention. Then a spotlight on obesity drugs

STAT

CHICAGO — This year’s scientific sessions on the latest research in cardiovascular disease began not with the buzzy new obesity drugs but with a sobering look at progress stalling or even reversing in common chronic illnesses. The overture to the American Heart Association’s conference, coming as the organization celebrates its 100th year, began with Valentin Fuster of Mount Sinai Hospital lamenting the predicted shift in overall cardiovascular disease burden,  worsenin

Hospitals 128
article thumbnail

Usage of AI With PET/CT Images Could Detect Impacts of Immunotherapy in Lung Cancer

Pharmacy Times

The risk of developing interstitial lung disease after immunotherapy was 6.5 times higher in individuals with high inflammation.

138
138
article thumbnail

Jazz's HER2 bispecific snags FDA nod, teeing up showdown with AZ and Daiichi's Enhertu

Fierce Pharma

A bispecific antibody has entered the HER2 fray with a differentiated profile from traditional agents and a chance to challenge AstraZeneca and Daiichi Sankyo’s star antibody-drug conjugate Enhertu | A bispecific antibody has entered the HER2 fray with a differentiated profile from traditional agents and a chance to challenge AstraZeneca and Daiichi Sankyo’s star ADC Enhertu.

FDA 128
article thumbnail

CVS, Glenview Capital reach deal that adds 4 board members

Fierce Healthcare

As CVS Health pushes to turn around its financial fortunes, it has entered into a deal with key investor Glenview Capital Management that will add four members to its board of directors. | As CVS Health pushes to turn around its financial fortunes, it has entered into a deal with key investor Glenview Capital Management that will add four members to its board of directors.

124
124